Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis
- 4 November 2020
- journal article
- review article
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 17 (1) , 31-46
Abstract
Over the past three decades, the mainstay of treatment for osteoporosis has been antiresorptive agents (such as bisphosphonates), which have been effective with continued administration in lowering fracture risk. However, the clinical landscape has changed as adherence to these medications has declined due to perceived adverse effects. As a result, decreases in hip fracture rates that followed the introduction of bisphosphonates have now levelled off, which is coincident with a decline in the use of the antiresorptive agents. In the past two decades, two types of anabolic agents (including three new drugs), which represent a novel approach to improving bone quality by increasing bone formation, have been approved. These therapies are expected to lead to a new clinical paradigm in which anabolic agents will be used either alone or in combination with antiresorptive agents to build new bone and reduce fracture risk. This Review examines the mechanisms of action for these anabolic agents by detailing their receptor-activating properties for key cell types in the bone and marrow niches. Using these advances in bone biology as context, the comparative effectiveness of these anabolic agents is discussed in relation to other therapeutic options for osteoporosis to better guide their clinical application in the future.Keywords
This publication has 176 references indexed in Scilit:
- The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 yearsJournal of Bone and Mineral Research, 2012
- Osteocytic network is more responsive in calcium signaling than osteoblastic network under fluid flowJournal of Bone and Mineral Research, 2011
- A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnoverJournal of Bone and Mineral Research, 2011
- Timing of Subsequent Fractures after an Initial FractureCurrent Osteoporosis Reports, 2010
- T Lymphocytes Amplify the Anabolic Activity of Parathyroid Hormone through Wnt10b SignalingCell Metabolism, 2009
- Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repairBone, 2009
- PTH and PTHrP signaling in osteoblastsCellular Signalling, 2009
- Mesodermal fate decisions of a stem cell: the Wnt switchCellular and Molecular Life Sciences, 2008
- Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complicationsOsteoporosis International, 2007
- Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on boneBone, 2007